Hikma Pharmaceuticals PLC (GB:HIK)
LSE:HIK
Holding GB:HIK?
Track your performance easily

Hikma Pharmaceuticals (HIK) Share Forecast & Price Target

41 Followers
See the Price Targets and Ratings of:

HIK Analyst Ratings

Moderate Buy
6Ratings
3 Buy
3 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Hikma
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HIK Stock 12 Month Forecast

Average Price Target

2,322.50p
▲(22.53% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is 2,322.50p with a high forecast of 2,845.00p and a low forecast of 2,000.00p. The average price target represents a 22.53% change from the last price of 1,895.50p.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1702":"1,702p","1988":"1,988p","2274":"2,274p","2560":"2,560p","2846":"2,846p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2845,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.85K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2322.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">2.32K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">2.00K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1702,1988,2274,2560,2846],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2024","6":"Apr<br/>2024","9":"Jul<br/>2024","12":"Oct<br/>2024","25":"Oct<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1904,1976.3846153846155,2048.769230769231,2121.153846153846,2193.5384615384614,2265.923076923077,2338.3076923076924,2410.6923076923076,2483.076923076923,2555.4615384615386,2627.846153846154,2700.2307692307695,2772.6153846153848,{"y":2845,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1904,1936.1923076923076,1968.3846153846155,2000.576923076923,2032.7692307692307,2064.9615384615386,2097.153846153846,2129.346153846154,2161.5384615384614,2193.730769230769,2225.923076923077,2258.1153846153848,2290.3076923076924,{"y":2322.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1904,1911.3846153846155,1918.7692307692307,1926.1538461538462,1933.5384615384614,1940.923076923077,1948.3076923076924,1955.6923076923076,1963.076923076923,1970.4615384615386,1977.8461538461538,1985.2307692307693,1992.6153846153845,{"y":2000,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2011.21,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1749.02,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1703.95,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1801.85,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1819.29,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1874.06,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1840.78,"date":1712275200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1936.63,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1925.76,"date":1717718400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1796.32,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1864.5,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1956,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1904,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target2,845pAverage Price Target2,323pLowest Price Target2,000p
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank
2,750p
Buy
45.08%
Upside
Reiterated
06/18/24
RBC Capital
2,375p
Hold
25.30%
Upside
Reiterated
04/29/24
CFRA
2,200p2,000p
Hold
5.51%
Upside
Reiterated
04/26/24
Hikma Pharmaceuticals Plc (HIK:LN) (HKMPF) PT Lowered to GBP20 at CFRACFRA analyst Wan Nurhayati lowered the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP20.00 (from GBP22.00) while maintaining a Hold rating.
J.P. Morgan
22p2,350p
Buy
23.98%
Upside
Reiterated
02/23/24
Hikma Pharmaceuticals Plc (HIK:LN) (HKMPF) PT Raised to GBP23.50 at JPMorganJPMorgan analyst James Gordon raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP23.50 (from GBP22.00) while maintaining a Overweight rating.

Best Analysts Covering Hikma Pharmaceuticals

Which Analyst Should I Follow If I Want to Buy GB:HIK and Sell After:
1 Month
xxx
Success Rate
7/15 ratings generated profit
47%
Average Return
+2.13%
assigned a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 46.67% of your transactions generating a profit, with an average return of +2.13% per trade.
3 Months
xxx
Success Rate
11/15 ratings generated profit
73%
Average Return
+7.55%
assigned a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +7.55% per trade.
1 Year
Success Rate
11/15 ratings generated profit
73%
Average Return
+6.93%
assigned a buy rating 2 months ago
Copying Peter Verdult's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +6.93% per trade.
2 Years
xxx
Success Rate
8/15 ratings generated profit
53%
Average Return
-3.45%
assigned a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 53.33% of your transactions generating a profit, with an average return of -3.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HIK Analyst Recommendation Trends

Rating
May 24
Jun 24
Jul 24
Aug 24
Sep 24
Strong Buy
0
0
0
0
0
Buy
1
3
3
4
3
Hold
6
6
3
6
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
9
6
10
8
In the current month, HIK has received 3 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. HIK average Analyst price target in the past 3 months is 2,322.50p.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

HIK Financial Forecast

HIK Earnings Forecast

The previous quarter’s earnings for HIK were 0.97p.
The previous quarter’s earnings for HIK were 0.97p.

HIK Sales Forecast

Next quarter’s sales forecast for HIK is 1.17B with a range of 1.17B to 1.17B. The previous quarter’s sales results were 1.24B. HIK beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.58% of the time in the same period. In the last calendar year HIK has Outperformed its overall industry.
Next quarter’s sales forecast for HIK is 1.17B with a range of 1.17B to 1.17B. The previous quarter’s sales results were 1.24B. HIK beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.58% of the time in the same period. In the last calendar year HIK has Outperformed its overall industry.

HIK Stock Forecast FAQ

What is GB:HIK’s average 12-month price target, according to analysts?
Based on analyst ratings, Hikma Pharmaceuticals PLC’s 12-month average price target is 2,322.50p.
    What is GB:HIK’s upside potential, based on the analysts’ average price target?
    Hikma Pharmaceuticals PLC has 22.53% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Hikma Pharmaceuticals PLC a Buy, Sell or Hold?
          Hikma Pharmaceuticals PLC has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Hikma Pharmaceuticals PLC’s share price target?
            The average share price target for Hikma Pharmaceuticals PLC is 2,322.50p. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is 2,845.00p ,and the lowest forecast is 2,000.00p. The average share price target represents 22.53% Increase from the current price of 1,895.5p.
              What do analysts say about Hikma Pharmaceuticals PLC?
              Hikma Pharmaceuticals PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Hikma Pharmaceuticals PLC?
                To buy shares of GB:HIK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis